The Home Depot, Inc. (HD): analysis and signal as of September 3, 2026
In short
The signal on The Home Depot comes out weak, with a rating of 3 out of 3, in a context of recovering profitability but unfavorable technical flows and leverage above the internal target. The reading combines a verification of the second-quarter results and caution on the macro and sector dynamic.
- Current signal
- weak (vote 3/3)
- Deterministic score
- +2.5 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : –, price : negative, risks : neutral
Triggered rules
| Rule | Weight |
|---|---|
| favors a high and durable return on invested capital (ROIC), a marker of a lasting moat | +2.0 |
| penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE | -1.0 |
| favors high gross profitability (gross profit / assets), a robust predictor of returns | +1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
Thesis
Home Depot retains a competitive advantage deemed wide and profitability is recovering, with adjusted EPS up 5.1 % and positive comparable sales. The stock nonetheless carries three handicaps: a sector penalized by the macro regime, leverage above the internal target of 2 times after the SRS and GMS acquisitions, and distribution technical flows with a price below the 50-day and 200-day averages. The expectation centers on a stabilization of the stock or on a catalyst tied to mortgage rates.
Bull case
The second-quarter results, verified on 18 August 2026, confirm the recovery: comparable sales up 1.7 %, including 1.3 % in the United States, adjusted EPS of 4.92 USD up 5.1 %, annual guidance reaffirmed, median analyst target of 379 USD, roughly +19 %, dividend yield of 2.9 %, wide competitive advantage recognized, and successful diversification toward the Pro customer base through SRS and GMS.
Bear case
Leverage exceeds the financial policy target of 2 times debt to EBITDA according to S&P, growth relies partly on acquisition scope rather than on organic comparable sales, valuation does not offer demonstrated margin of safety, and intraday flows over six months at -20.4 % reveal continuous institutional distribution in a macro regime that penalizes discretionary consumption and rate-sensitive stocks.
Scenarios
Bull scenario at 25 %, target 380 USD based on a decline in mortgage rates that unlocks residential mobility and on the maintenance of multiples. Central scenario at 50 %, with a range of 300 to 340 USD, dividend collected and weak growth. Bear scenario at 25 %, maximum loss of -20 % toward 255 USD if comparable sales turn negative again, with a derating effect and constrained deleveraging.
Risks
The main risks center on a return of comparable sales to negative territory, on a persistent rise in mortgage rates that would curb residential mobility, on further pressure on discretionary consumption, on the execution of deleveraging beyond the internal target, and on the continuation of institutional distribution flows in a deteriorated technical context below the 50-day and 200-day averages.
Market positioning (short sellers)
- Short interest / shares outstanding
- 1.04 %
- Days to cover
- 3.26
- Settlement date
- 2026-08-14
- Source
- FINRA (disseminated on 2026-08-26)
Upcoming catalysts
| Date | Description |
|---|---|
| Q3 fiscal 2026 results |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| weak (3/3) | Unchanged point. No prior verdict, data verified on 03/09/2026 without signal modification. Personal analysis, not advice. |
Frequently asked questions
What does a weak signal on this stock mean?
A weak signal reflects a cautious reading: the fundamental dynamic is confirmed by the second-quarter results, but technical indicators, the leverage level, and the macro sector context remain unfavorable. The rating of 3 out of 3 captures this imbalance between recovered fundamentals and a degraded chart configuration, without prescribing any action.
Why does leverage appear among the handicaps?
After the SRS and GMS acquisitions, the debt to EBITDA ratio exceeds the financial policy target set at 2 times according to S&P. This overshoot increases the balance sheet sensitivity to a rise in rates and limits financial flexibility, which constitutes a point of vigilance for the deleveraging trajectory.
What is the weight of the macro context in the analysis?
The macro regime influences the stock in two ways. On one hand, mortgage rates condition residential mobility and therefore renovation projects. On the other hand, sensitivity to discretionary consumption exposes the model to a slowdown. Technical flows over six months at -20.4 % reflect this persistent pressure.
Is the competitive advantage called into question?
The competitive advantage remains described as wide, supported by diversification toward the Pro customer base and by the capacity to generate positive comparable sales even in a difficult macro phase. The successful Pro diversification through SRS and GMS strengthens this positioning, without however offsetting the balance sheet and flow constraints.
What is the contribution of the SRS acquisition?
The SRS acquisition broadens exposure to the Pro customer base and delivers a revenue contribution that explains part of the observed growth. This contribution comes from scope, which nuances the organic reading of the positive comparable sales of 1.7 % in the second quarter.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — 10-Q (SEC · 10-Q)
- — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers (SEC · 8-K)
- — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; 7.01 Reg… (SEC · 8-K)
- — 10-Q (SEC · 10-Q)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 3, 2026; this page was completed on September 4, 2026 at 07:43 (UTC).
- Interests: no position in the stock analysed (HD) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: CVS Health Corporation (CVS)
- All analysed stocks
- Public methodology